W1 examines the technologies, infrastructures and instruments through which Europe is attempting to industrialise the clean transition: green hydrogen and its derivatives, industrial heat and process electrification, circular materials, energy storage at grid scale, and the cross-cutting question of how Europe converts its scientific leadership in clean technologies into sovereign industrial capability. The window takes as its starting point the observation that Europe holds world-class research positions across many clean-technology domains, with around a quarter of global clean-tech patents and a leading share of the world’s wind and heat-pump technology companies, but consistently struggles to convert these into competitive manufacturing at scale. It examines where, along the continuum from research and pilot-line through industrial demonstration to commercial deployment, the clean industrial stack most consistently breaks, and what the FP10 to ECF interface should do differently.

The window is co-organised with EFFRA (European Factories of the Future Research Association) and MANUFUTURE (the European Technology Platform for advanced manufacturing), the two institutional anchors of European manufacturing R&I.

There will be five discussions tables, that follows fire-starter presentations. The five tables address the common diagnostic template through the clean-industrial lens.

Table 1 (Stack Breakpoints) maps where, along the continuum from research and pilot-line through industrial demonstration to commercial deployment, European clean-technology programmes most consistently fail to progress, with attention to the demonstration-to-deployment handover, the industrial scale-up question, and the regulatory and permitting environment.

Table 2 (Context Conditions) examines the systemic enablers, finance for first-of-a-kind plants, energy cost competitiveness, permitting frameworks, demand formation through public procurement and lead markets, technology infrastructure, critical raw materials supply, and skills, that determine whether clean technologies progress through the stack.

Table 3 (What Works) identifies European clean-industrial successes and the structural conditions that made them possible, drawing on cases from offshore wind, green hydrogen, batteries, and circular manufacturing.

Table 4 (FP10 and ECF Asks) translates the diagnosis into specific design recommendations for the Clean Transition policy window of the ECF, the Industrial Decarbonisation Bank, the Innovation Fund, and FP10 Pillar 2 clusters bearing on clean industry.

Table 5 (Acting Differently) surfaces concrete, programme-language-ready interventions, from “made in Europe” procurement criteria to fast-track permitting, dedicated technology infrastructure instruments, and carbon contracts for difference.

W2 examines where Europe’s digital and compute capability system breaks, from frontier AI and software research through the compute-intensive validation stages where models are trained and benchmarked, to the commercial scale-up where European deep-tech companies must compete with US and Chinese hyperscalers. The window addresses three interlocking dynamics: the access gap on large-scale compute infrastructure at competitive cost, the scale-up barrier created by 27 fragmented national digital markets, and the asymmetric regulatory compliance burden falling disproportionately on European SMEs and startups under the AI Act, Data Act and Cyber Resilience Act. The window also examines the value-chain dimension of compute sovereignty, including chip design, software stacks, and the talent base that underpins European AI competitiveness.

The window is co-organised with ADRA, the European public-private partnership for AI, data and robotics, which represents the operational backbone of Europe’s digital R&I community.

There will be five discussions tables, that follows fire-starter presentations. The five tables address the common diagnostic template through the digital and compute lens.

Table 1 (Stack Breakpoints) maps where, along the continuum from frontier research to commercial scale, the European digital stack most consistently fails to progress, with attention to compute access at TRL 4–7, market fragmentation, and regulatory asymmetry.

Table 2 (Context Conditions) examines compute access rules, Series B+ patient capital, AI Act and Data Act compliance economics, digital procurement frameworks, and AI talent retention.

Table 3 (What Works) identifies European digital successes and the structural conditions that enabled them, drawing on cases from semiconductor manufacturing, edge AI, fintech, and the platforms that have scaled in Europe.

Table 4 (FP10 and ECF Asks) translates the diagnosis into specific design recommendations for the Digital Leadership policy window of the ECF, the design of ADRA 2.0, EuroHPC access rules for commercial validation workloads, and FP10 Pillar 2 clusters bearing on digital.

Table 5 (Acting Differently) surfaces concrete, programme-language-ready interventions, from compute access vouchers to procurement reform and AI talent instruments.

W3 examines the European health innovation continuum, from biomedical research through clinical development to regulatory approval, reimbursement and patient access. The window takes as its starting point the observation that European health research is genuinely world-class at the frontier, but that the path from a validated scientific result to a deployed health intervention runs through clinical trial coordination, regulatory pathways, health technology assessment and reimbursement frameworks that often differ across Member States. The window also considers the structural questions that condition the entire stack: the convergence of AI, sensors and biodata that is transforming diagnostics and care; the manufacturing scale-up gap from clinical proof-of-concept to commercial production; and the absorptive capacity of healthcare systems that must ultimately deploy these innovations at scale.

The window is co-organised with the Innovative Health Initiative (IHI), the European public-private partnership operating at the interface between health research, regulators, payers and industry.

The five tables address the common diagnostic template through the health-innovation lens.

Table 1 (Stack Breakpoints) maps where, along the continuum from biomedical research to patient deployment, the European health stack most consistently fails to progress, with attention to clinical trial coordination, regulatory science, health technology assessment, manufacturing scale-up, and healthcare system absorption.

Table 2 (Context Conditions) examines HTA process design (national versus EU), regulatory sandboxes for digital health and AI, hospital procurement frameworks, federated health data infrastructure, and the talent and skills base supporting European health R&I.

Table 3 (What Works) identifies European health innovation successes and the structural conditions that made them possible, drawing on cases from COVID vaccine scale-up, federated data infrastructures (Finland, Estonia), and Nordic procurement models.

Table 4 (FP10 and ECF Asks) translates the diagnosis into specific design recommendations for the Health and Biotechnology policy window of the ECF, the implementation of the EU HTA Regulation, the next phase of IHI, and the relationship between FP10 and the ECF for health innovation specifically.

Table 5 (Acting Differently) surfaces concrete, programme-language-ready interventions.